| Trial ID: | L0317 |
| Source ID: | NCT05053165
|
| Associated Drug: |
LB-P6
|
| Title: |
A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Rheumatoid Arthritis|Non-Alcoholic Steatohepatitis
|
| Interventions: |
Drug: LB-P6|Drug: LB-P8|Drug: Placebo
|
| Outcome Measures: |
To assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants through adverse events as assessed by NCI-CTCAE v5.0
|
| Sponsor/Collaborators: |
LISCure Biosciences|Novotech (Australia) Pty Limited
|
| Gender: |
All
|
| Age: |
18 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
30
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
November 12, 2021
|
| Completion Date: |
June 1, 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
December 30, 2021
|
| Locations: |
Cmax Clinical Research, Adelaide, Australia
|
| URL: |
https://ClinicalTrials.gov/show/NCT05053165
|
